AGCO, Your Agriculture Company (NYSE:AGCO), a worldwide manufacturer and distributor of agricultural equipment and infrastructure, announced today that it will participate in Jefferies Virtual Industrials Conference on Wednesday, August 5, 2020. The conference will include a presentation by Andy Beck, AGCO's Senior Vice President and Chief Financial Officer at 9:45 a.m. E.T. Investors may listen to a live webcast of the presentation by accessing the webcast button in the "Investors" section of the Company’s website at https://www.agcocorp.com/company/investors.aspx. The webcast will also be archived immediately afterwards.
AGCO (NYSE:AGCO) is a global leader in the design, manufacture and distribution of agricultural solutions and delivers high-tech solutions for farmers feeding the world through its full line of equipment and related services. AGCO products are sold through five core brands, Challenger®, Fendt®, GSI®, Massey Ferguson® and Valtra®, supported by Fuse® smart farming solutions. Founded in 1990 and headquartered in Duluth, Georgia, USA, AGCO had net sales of $9.0 billion in 2019. For more information, visit https://www.AGCOcorp.com. For company news, information and events, please follow us on Twitter: @AGCOCorp. For financial news on Twitter, please follow the hashtag #AGCOIR.
Please visit our website at www.agcocorp.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200731005376/en/
PISCATAWAY, N.J., July 24, 2020 /PRNewswire/ -- GenScript, the world's leading gene synthesis provider, today announced that it will highlight recent innovations using designed mutant libraries to advance neurodegenerative disease treatment at the Protein Engineering Congress USA 2020. During a headline keynote by Dr. Meredith Jackrel of Washington University and a GenScript-hosted panel, experts will review how a first-in-class semiconductor-based DNA synthesis platform is advancing protein engineering. They will also discuss GenScript's precision DNA mutant libraries for improving protein properties such as functional activities and binding affinities for biosynthetic, therapeutic, and diagnostic applications.
"Our novel semiconductor-based DNA synthesis platform allows mutant library construction with precise control over codon usage, thereby enabling the minimization of codon bias and uneven distribution of amino acids as well as preventing the introduction of unwanted or stop codons," said Maung Nyan Win, PhD, Sr. Field Applications Scientist, GenScript. "This customizable codon usage will inherently improve the library quality significantly, saving researchers valuable time and effort during the screening and characterization process, and thus ultimately reducing costs and time to market."
During the Congress:
On July 28 at 12 p.m. EDT, Meredith Jackrel, PhD, assistant professor in the Department of Chemistry at Washington University in St. Louis, presents the headline keynote on behalf of GenScript titled, "Engineering protein disaggregases to counter the protein misfolding that underpins neurodegeneration." Dr. Jackrel discusses utilizing protein disaggregases to counter the misfolding that underpins neurodegeneration in Amyotrophic Lateral Sclerosis (ALS) and Parkinson's disease. By screening large libraries of Hsp104 variants generated from GenScript's semiconductor-based DNA synthesis platform that comprehensively cover sequence space, Dr. Jackrel aims to uncover variants with improved properties and learn more about the mechanisms of Hsp104 potentiation. Hsp104 is a protein disaggregase from yeast that Dr. Jackrel and team have engineered to counter the misfolding of proteins that aggregate in ALS and Parkinson's disease.
On July 27 at 2:30 p.m. EDT, GenScript hosts the panel "Tailor-Made Mutant Libraries for Precision Engineering," featuring Maung Nyan Win, PhD, Sr. Field Applications Scientist, GenScript; Nicky Caiazza, Co-founder and CSO of Cellibre; and Iman Farasat, Associate Director, Biologics Discovery, The Janssen Pharmaceutical Companies of Johnson & Johnson. The panel will discuss the methods, benefits, and uses of an advanced, arrayed semiconductor-based DNA synthesis platform for construction of high-quality mutant libraries that are devoid of unwanted mutants. The panel will also more broadly discuss the utility of these mutant libraries for biosynthetic and therapeutic applications.
"With the Protein Engineering Congress being the place for showcasing the latest innovations for industrial biocatalysis and synthetic biology-based product development, we are incredibly excited to have market leader GenScript as our headline partner, with Dr. Meredith Jackrel delivering the Day 2 keynote," said Mark Gavhure, Director of Commercial Partnerships for Kisaco Research, sponsor of the event.
The Protein Engineering Congress 2020 gathers scientific and industry leaders to discuss innovations and new techniques in protein and enzyme engineering in industrial applications from pharmaceuticals to specialty chemicals to food and beverages and other consumer goods. Dr. Frances Arnold, recipient of the 2018 Nobel Prize for Chemistry and Linus Pauling Professor, Chemical Engineering, Bioengineering & Biochemistry, will keynote the event.
GenScript is a leading contract research organization providing gene, peptide, protein, CRISPR, and antibody reagents to scientists in over 100 countries worldwide. Since its foundation in 2002, GenScript has grown exponentially through partnerships with scientists conducting fundamental life science and translational biomedical research, as well as early stage pharmaceutical development. With a mission to improve the health of mankind and nature through biotechnology, the company has developed the best-in-class capacity and capability for producing biological reagents in order to Make Research Easy for all scientists. For more information, visit www.genscript.com.
Contact:CorporateEric Wang, vice president of marketingGenScript(732) 885-9188 ext. email@example.comMediaSusan ThomasPrincipal, Endpoint Communications(619) firstname.lastname@example.org
View original content to download multimedia:https://www.prnewswire.com/news-releases/genscript-highlights-tailor-made-mutant-libraries-for-therapeutic-applications-at-protein-engineering-congress-301099634.html
SOURCE Genscript Biotech Corporation
(RTTNews) - The Taiwan stock market turned lower again on Tuesday, one session after halting the four-day losing streak in which it had lost more than 200 points or 1.7 percent. The Taiwan Stock Exchange now rests just above the 12,860-point plateau and it's looking at a green light for Wednesday's trade.
The global forecast for the Asian markets is mixed to higher on renewed optimism for economic stimulus in the face of the coronavirus pandemic. The European markets were down and the U.S. bourses were up and the Asian markets figure to follow the latter lead.
The TSE finished modestly lower on Tuesday following losses from the financial shares and cement companies, while the technology stocks were mixed.
For the day, the index sank 45.97 points or 0.36 percent to finish at 12,862.37 after trading between 12,862.37 and 12,917.75.
Among the actives, Cathay Financial collected 0.13 percent, while Mega Financial shed 0.36 percent, Fubon Financial eased 0.12 percent, First Financial lost 0.49 percent, E Sun Financial dipped 0.20 percent, Taiwan Semiconductor Manufacturing Company skidded 1.42 percent, United Microelectronics Corporation added 0.65 percent, Hon Hai Precision was up 0.12 percent, Largan Precision rose 0.16 percent, Catcher Technology sank 0.83 percent, MediaTek gained 0.72 percent, Formosa Plastic gained 0.51 percent, Asia Cement was down 0.49 percent, Taiwan Cement slid 0.25 percent and CTBC Financial and Formosa Chemical were unchanged.
The lead from Wall Street is positive as stocks opened higher on Tuesday, fell from afternoon highs but still ended solidly in the green - cutting into the previous session's losses.
The Dow climbed 113.37 points or 0.40 percent to finish at 28,308.79, while the NASDAQ added 37.61 points or 0.33 percent to end at 11,516.49 and the S&P 500 gained 16.20 points or 0.47 percent to close at 3,443.12.
The rebound on Wall Street comes amid renewed optimism about lawmakers in Washington reaching an agreement on a new stimulus bill as Democrats and Republicans work to narrow their differences.
Reports that Moderna's coronavirus vaccine could be available for emergency use in December if it gets positive results from its interim trial next month further aided sentiment.
Crude oil futures moved higher on Tuesday on expectations of a drop in U.S. crude inventories and that OPEC and its allies will scale back production. West Texas Intermediate Crude oil futures for December ended up $0.64 or 1.6 percent at $41.70 a barrel.